Literature DB >> 2820125

Identification of an Epstein-Barr virus early gene encoding a second component of the restricted early antigen complex.

G R Pearson, J Luka, L Petti, J Sample, M Birkenbach, D Braun, E Kieff.   

Abstract

When the latent Epstein-Barr virus (EBV) genome in B95-8 cells is induced into a replicative phase, two abundant early RNAs are transcribed rightward from the EBV BamHI H DNA fragment into BamHI F. Analysis of cDNA clones prepared from the RNA of cells replicating EBV revealed that both RNAs contain the BHRF1 open reading frame. Part of BHRF1, cloned into a prokaryotic fusion protein expression vector, expressed a fusion protein in Escherichia coli and the purified fusion protein was used to generate a monoclonal antibody against BHRF1. This antibody was then employed to characterize the protein encoded by BHRF1 in cells replicating EBV. The monoclonal antibody reacted with a 17-kDa protein component of the restricted early antigen (EA) complex. The distribution of the protein in cells was similar to that noted when sera from patients with African Burkitt's lymphoma were used to stain these cells. The protein was synthesized before the major 47-56 kDa protein associated with the diffuse component of EA in superinfected Raji cells. All human sera containing antibodies to EA as determined by immunofluorescence (IF) reacted with the protein as did some sera determined to be anti-VCA positive and anti-EA negative by IF. The predicted amino acid sequence of the protein has characteristics which suggest that it is a membrane protein. It also has significant homology with both the anchor region of polyoma middle T antigen and with the predicted protein product of the bcl-2 mRNA activated by the 14/18 chromosome translocation characteristic of follicular lymphomas. This latter homology is extensive and colinear, suggesting common evolution and function. However, neither a mRNA which could efficiently translate the BHRF1 protein nor the BHRF1 protein could be detected in latently infected cells. Thus, the bcl-2 predicted protein is similar to an EBV protein synthesized in the early phase of virus infection.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2820125     DOI: 10.1016/0042-6822(87)90055-9

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  68 in total

1.  Antiapoptotic herpesvirus Bcl-2 homologs escape caspase-mediated conversion to proapoptotic proteins.

Authors:  D S Bellows; B N Chau; P Lee; Y Lazebnik; W H Burns; J M Hardwick
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

2.  Expression of two related viral early genes in Epstein-Barr virus-associated tumors.

Authors:  S A Xue; Q L Lu; R Poulsom; L Karran; M D Jones; B E Griffin
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

3.  The Epstein-Barr virus R transactivator (Rta) contains a complex, potent activation domain with properties different from those of VP16.

Authors:  J M Hardwick; L Tse; N Applegren; J Nicholas; M A Veliuona
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

4.  The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle.

Authors:  A L Lear; M Rowe; M G Kurilla; S Lee; S Henderson; E Kieff; A B Rickinson
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

5.  A selectable marker allows investigation of a nontransforming Epstein-Barr virus mutant.

Authors:  A Marchini; J I Cohen; F Wang; E Kieff
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

6.  A case of Epstein-Barr Virus (EBV)-associated thymic carcinoid and investigation of existence of EBV-infected cells in thymus and thymic tumors.

Authors:  Hiroaki Takeuchi; Hiroshi Fujita; Fumio Iwasaki; Takako Takeuchi; Ken-Ichi Imadome; Toshika Okumiya; Tomohiro Matsui; Mutsuo Takahashi
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

7.  Assessment of Epstein-Barr virus in blood from patients with multiple sclerosis.

Authors:  Gloudina M Hon; Mogamat S Hassan; Susan J van Rensburg; Rajiv T Erasmus; Tandi E Matsha
Journal:  Metab Brain Dis       Date:  2012-03-10       Impact factor: 3.584

Review 8.  Relationship between antibody production to Epstein-Barr virus (EBV) early antigens and various EBV-related diseases.

Authors:  T Ooka; M de Turenne-Tessier; M C Stolzenberg
Journal:  Springer Semin Immunopathol       Date:  1991

9.  The ability of BHRF1 to inhibit apoptosis is dependent on stimulus and cell type.

Authors:  L Foghsgaard; M Jäättelä
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

10.  The apoptotic suppressor P35 is required early during baculovirus replication and is targeted to the cytosol of infected cells.

Authors:  P A Hershberger; D J LaCount; P D Friesen
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.